검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Antibody-Drug Conjugates (Antibody-Drug Conjugates) SOLTI Breast Cancer Research Group·Advanced or Metastatic Solid Tumou… ORR 86%·t½ 7 h |
|---|---|
Overview Program | Antibody-Drug Conjugates |
Overview Company | SOLTI Breast Cancer Research Group |
Overview Modality | ANTIBODY |
Overview Target | Advanced or Metastatic Solid Tumour |
Overview Indication | Metastatic Breast Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | ADC target assessment on CTCs using epitope-independent enrichment |
MoA Biomarker | PD-L1 was highly expressed in MDA-MB-231 and HCC1937 but low |
PK/PD Half-life | 7 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Infectious Complications of Antibody-Drug Conjugates: A Review of Safety Data from FDA-Approved Agents.. With fifteen agents now FDA-approved and indications expanding into earlier treatment lines, antibody-drug conjugates (ADCs) represent a rapidly growing class of targeted cancer therapeutics. Despite their selective mechanism of action, infectious complications are clinically significant and ha… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 86% |
Clinical ORR | 86% |
Clinical PFS | 14.6 |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT00866047 |
Clinical Data Tier / Score | A · 71 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Antibody-Drug Conjugates (Antibody-Drug Conjugates) SOLTI Breast Cancer Research Group·Advanced or Metastatic Solid Tumou… ORR 86%·t½ 7 h |
|---|---|
Overview Program | Antibody-Drug Conjugates |
Overview Company | SOLTI Breast Cancer Research Group |
Overview Modality | ANTIBODY |
Overview Target | Advanced or Metastatic Solid Tumour |
Overview Indication | Metastatic Breast Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | ADC target assessment on CTCs using epitope-independent enrichment |
MoA Biomarker | PD-L1 was highly expressed in MDA-MB-231 and HCC1937 but low |
PK/PD Half-life | 7 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Infectious Complications of Antibody-Drug Conjugates: A Review of Safety Data from FDA-Approved Agents.. With fifteen agents now FDA-approved and indications expanding into earlier treatment lines, antibody-drug conjugates (ADCs) represent a rapidly growing class of targeted cancer therapeutics. Despite their selective mechanism of action, infectious complications are clinically significant and ha… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 86% |
Clinical ORR | 86% |
Clinical PFS | 14.6 |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT00866047 |
Clinical Data Tier / Score | A · 71 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교